Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Manufacturers must conduct studies proving their generic versions are bioequivalent to the brand-name product, then submit these for FDA approval
Patients in PIONEER 5 had moderate renal impairment (estimated glomerular filtration rate [eGFR] 3059 ml/min/1.73 m 2 )
Animal studies used doses up to 1.1 mg per kilogram of body weight with no adverse effects observed
Trial averages were measured at 68 weeks for semaglutide and 72 weeks for tirzepatide
US$ 21.85
US$ 29.29
US$ 27.41
US$ 24.77
US$ 22.96
US$ 28.50
US$ 21.01
